Adeline Bouard

Besancon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Regorafenib and metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer: results from the REPROGRAM-01 single-arm phase II trial.

Regorafenib and metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer: results from the REPROGRAM-01 single-arm phase II trial.

Journal: ESMO gastrointestinal oncology

Published: July 06, 2026

Clinical and biological determinants of multimodal metronomic chemotherapy efficacy in chemo-refractory gastrointestinal cancers.

Clinical and biological determinants of multimodal metronomic chemotherapy efficacy in chemo-refractory gastrointestinal cancers.

Journal: International journal of cancer

Published: March 30, 2025

Liver metastases of colorectal cancer contain different subsets of tissue-resident memory CD8 T cells correlated with a distinct risk of relapse following surgery.

Liver metastases of colorectal cancer contain different subsets of tissue-resident memory CD8 T cells correlated with a distinct risk of relapse following surgery.

Journal: Oncoimmunology

Published: January 23, 2025

AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies.

AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies.

Journal: Frontiers in immunology

Published: September 21, 2024

Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials.

Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials.

Journal: Cancer research communications

Published: April 28, 2024

Targeting SALL4 with an HLA Class I-Restricted TCR for Cancer Immunotherapy.

Targeting SALL4 with an HLA Class I-Restricted TCR for Cancer Immunotherapy.

Journal: Cancer immunology research

Published: February 28, 2024

Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.

Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.

Journal: BMJ oncology

Published: February 24, 2023

The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age.

The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age.

Journal: Frontiers in immunology

Published: February 07, 2023

Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy.

Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy.

Journal: Oncoimmunology

Published: November 17, 2022

SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features.

SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features.

Journal: Molecular oncology

Published: August 18, 2022

CD8+ CD226high T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery.

CD8+ CD226high T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery.

Journal: Cellular & molecular immunology

Published: July 04, 2022

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.

Journal: Frontiers in oncology

Published: May 31, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026